Business
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025.
About this update from Amgen Inc.
[{"type":"text","content":"∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.","length":121,"tagName":"p"},{"type":"text","content":"LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025.","length":286,"tagName":"p"},{"type":"image","alt":"Accord Healthcare Logo (PRNewsfoto/Accord Healthcare)","displaySize":"","headline":null,"caption":"Accord Healthcare Logo (PRNewsfoto/Accord Healthcare)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":177,"url":"https://media.zenfs.com/en/prnewswire.com/5ea47879f09c648949e487c0a9cdc2e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M2Wat7LcVdIo9jQudGG6UA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5ea47879f09c648949e487c0a9cdc2e0","width":400,"height":177}},"href":"https://mma.prnewswire.com/media/2581239/Accord_Healthcare_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Both medicines were approved by the European Medicines Agency (EMA) in September of this year following trials versus their reference product showing they are highly similar to the Prolia® (Amgen).","length":197,"tagName":"p"},{"type":"text","content":"Denosumab marks the company's second biosimilar launch within its bone health portfolio, further expanding Accord's commitment to improving patient access to high-quality, cost-effective medicines in areas of high clinical need.","length":236,"tagName":"p"},{"type":"text","content":"Supporting clinicians and healthcare systems in bone health","length":59,"tagName":"p"},{"type":"text","content":"Osvyrti (denosumab) available as a 60 mg pre-filled syringe is indicated for1:","length":78,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures.","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"The treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.","length":119,"tagName":"p"}]},{"val":[{"type":"text...